Cell And Gene Therapies Demand Cryogenic Shipping
Cryogenic systems grow at 12.2% against a market at 9.0%, driven by autologous cell therapies and viral vector products that must hold minus 150 degrees or lower from apheresis to infusion. Each shipment is patient-specific and irreplaceable, so there is no acceptable failure rate and no substitute consignment waiting. Dry vapour shippers and liquid nitrogen dewars carry most of this volume today, with condition monitoring and chain of identity documentation treated as part of the packaging rather than an add-on. Volumes are small and the value per shipment is extraordinary. Nothing about it resembles parcel shipping. Much of this also feeds into the passive temperature controlled packaging solutions market, which MMA expects to grow at 9.6% a year through 2036.
Market Impact: About 50% of approvals need it








